Allied Minds and Bristol-Myers Squibb form new enterprise
- Details
- Category: Bristol-Myers Squibb
Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) have announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.
Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics.
Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
- Details
- Category: Pfizer
Pfizer Inc. has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.
Bayer continues positive business development
- Details
- Category: Bayer
The Bayer Group was again successful in the second quarter of 2014. Sales of the Bayer Group rose by 0.9 percent in the second quarter of 2014 to EUR 10,458 million (Q2 2013: EUR 10,360 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales advanced by 6.3 percent.
Bristol-Myers Squibb reports second quarter 2014 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company's key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; and the initiation of several research collaborations that will strengthen the company's leadership position in immuno-oncology.
Merck strengthens commitment to Chinese growth market
- Details
- Category: Merck Group
Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.
More Pharma News ...
- MedImmune and Advaxis partner on immuno-oncology combination clinical trial
- AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
- Novartis maintained strong innovation momentum in second quarter
- Pfizer to Acquire InnoPharma, Inc.
- Novartis to license Google "smart lens" technology
- Abbott to sell its developed markets branded generics pharmaceuticals business to Mylan
- CliniWorks forms a strategic alliance with Pfizer